200563-87-7

Basic information

• Product Name: 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine
• Synonyms: 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine;Methyl[4-[[(4-Methylphenyl)sulfonyl]oxy]butyl]carbaMic Acid
• CAS NO: 200563-87-7
• Molecular Formula: C₁₇H₂₇NO₅S
• Molecular Weight: 343.4384
• Product Categories: Aliphatics;Amines;Miscellaneous Reagents
• Mol File: 200563-87-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine(200563-87-7)
• EPA Substance Registry System: 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine(200563-87-7)

Safety Data

• Hazardous Substances Data: 200563-87-7(Hazardous Substances Data)

Usage

Description

3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine, with the CAS number 200563-87-7, is an organic compound that plays a significant role in various chemical reactions and processes. It is characterized by its unique chemical structure, which includes a toluenesulfonate group, a methyl group, and a tert-butyloxycarbonyl (Boc) protecting group attached to a propylamine backbone. This structure endows the compound with specific reactivity and properties that make it valuable in the field of organic synthesis.

Uses

Used in Organic Synthesis:
3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, such as nucleophilic substitutions, eliminations, and rearrangements, which can lead to the formation of diverse molecular structures with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine is used as a building block for the synthesis of complex drug molecules. Its reactivity and functional groups can be exploited to create new compounds with potential therapeutic properties, contributing to the development of novel medications for various diseases and conditions.
Used in Chemical Research:
3-(p-Toluenesulfonate)-N-methyl-N-boc-propylamine is also utilized in academic and industrial research settings as a model compound for studying various aspects of organic chemistry, such as reaction mechanisms, stereochemistry, and the influence of functional groups on reactivity. This helps chemists gain a deeper understanding of the underlying principles governing chemical reactions and can lead to the discovery of new synthetic methods and strategies.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 42042-68-2 4-(N-methylamino)butan-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 
• 99207-32-6 4-(N-tert-Butyloxycarbonyl-N-methylamino)butanol 

Downstream Products

• 740873-20-5 methyl-{4-[4-(3-nitrophenyl)piperazin-1-yl]butyl}carbamic acid tert-butyl ester 
• 740873-29-4 N-[3-(4-{4-[methyl(2-methylpropane-1-sulfonyl)amino]butyl}piperazin-1-yl)phenyl]acetamide 
• 740873-27-2 2-methylpropane-1-sulfonic acid methyl-{4-[4-(3-nitrophenyl)piperazin-1-yl]butyl}amide 
• 740873-28-3 2-methylpropane-1-sulfonic acid {4-[4-(3-aminophenyl)piperazin-1-yl]butyl}methylamide 

Relevant articles and documents

HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression

We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of anxiety and depression, which is now in Phase III clinical trials for generalized anxiety disorder (GAD). The discovery of 20m (PRX-00023), N-{3-[4-(4- cyclohexylmethanesulfonylaminobutyl)-piperazin-1-yl]phenyl}acetamide, and its backup compounds, followed a new paradigm, driving the entire discovery process with in silico methods and seamlessly integrating computational chemistry with medicinal chemistry, which led to a very rapid discovery timeline. The program reached clinical trials within less than 2 years from initiation, spending less than 6 months in lead optimization with only 31 compounds synthesized. In this paper we detail the entire discovery process, which started with modeling the 3D structure of 5-HT1A using the PREDICT methodology, and then performing in silico screening on that structure leading to the discovery of a 1 nM lead compound (8). The lead compound was optimized following a strategy devised based on in silico 3D models and realized through an in silico-driven optimization process, rapidly overcoming selectivity issues (affinity to 5-HT1A vs α1-adrenergic receptor) and potential cardiovascular issues (hERG binding), leading to a clinical compound. Finally we report key in vivo preclinical and Phase I clinical data for 20m tolerability, pharmacokinetics, and pharmacodynamics and show that these favorable results are a direct outcome of the properties that were ascribed to the compound during the rational structure-based discovery process. We believe that this is one of the first examples for a Phase III drug candidate that was discovered and optimized, from start to finish, using in silico model-based methods as the primary tool.